Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy
You may also be interested in...
Wyeth OTC Loratadine Launch Unaffected By ANDA Exclusivity Issues – Exec
Wyeth Consumer Healthcare, which reported sluggish third quarter sales, could experience a big revenue boost late in Q4 if its plans to launch OTC loratadine upon expiration of Schering-Plough's patent remain on track
Wyeth OTC Loratadine Launch Unaffected By ANDA Exclusivity Issues – Exec
Wyeth Consumer Healthcare, which reported sluggish third quarter sales, could experience a big revenue boost late in Q4 if its plans to launch OTC loratadine upon expiration of Schering-Plough's patent remain on track
Wyeth OTC Loratadine Launch Unaffected By ANDA Exclusivity Issues – Exec
Wyeth Consumer Healthcare, which reported sluggish third quarter sales, could experience a big revenue boost late in Q4 if its plans to launch OTC loratadine upon expiration of Schering-Plough's patent remain on track